Huons, a subsidiary of Huons Global, said Wednesday that it has signed a license agreement with Laboratoires SMB S.A, a Belgium pharmaceutical company, to market its Zephirus capsule, an asthma treatment.
|Officials from Laboratoires SMB S.A and Huons pose after signing the license agreement.|
Zephirus is a fixed-dose combination of Budesonide, an inhaled corticosteroid formulation that alleviates lung inflammation, and Salmeterol Xinafoate, a persistent long-acting b2-agonist characterized by a rapid bronchodilation effect.
According to SMB’s research, Zephirus showed similar pulmonary deposition amount even in small doses when compared to conventional dry powder inhalers. The dosage used was also less than the national average.
The treatment uses Axahaler as an inhaler, which allows the patients to check if they have appropriately taken the medication through sound, visual and taste. Also, the device and the capsule are entirely separated, which makes it easier to clean and dry after use, making it more hygienic.
“Respiratory disease is a disease that greatly affects the quality of life,” Huons CEO Um Key-an said. “Under Huons' corporate vision of providing a medical solution for human health, our company has entered into an exclusive licensing agreement with SMB to market Zephirus, expanding the selection of respiratory disease treatments for patients.”